Skip to content

AcuraBio expands cGMP plasmid DNA CDMO services with Cytiva’s latest single-use purification technology to alleviate supply constraints for mRNA and cell & gene therapies

BRISBANE, Australia
Jon Ince (left), General Manager, Australia & New Zealand, Cytiva and Guillaume Herry (right), CEO of AcuraBio, at the contract signing ceremony

-AcuraBio selects Cytiva’s latest two-step purification protocol to offer a productive plasmid DNA service to its customers globally to alleviate supply constraints for mRNA and cell & gene therapies
-The latest purification technology will offer efficient processing time for plasmid DNA production

AcuraBio, a leading Australian biopharmaceutical contract development and manufacturing organization (CDMO), will provide a cGMP plasmid DNA CDMO service to the world using Cytiva’s new process platform technology.

AcuraBio expects to produce more plasmid DNA for its customers around the world using Cytiva’s latest bacterial plasmid two-step purification protocol. The new protocol features single-use purification technology which delivers efficiency, high purity level outcome and sustainable process.[1]

Guillaume Herry, CEO of AcuraBio says: “We are very excited to implement Cytiva’s latest technology especially because the access and production of plasmid DNA has been a bottleneck in the advanced therapy market. We intend to bring biotechs and biopharma companies a more high-quality plasmid DNA quicker than before to help the development of new therapies such as viral vectors and mRNA.”

Jon Ince, General Manager, Commercial, Australia and New Zealand, Cytiva, says: “The adoption of Cytiva’s FlexFactory configurable manufacturing train, within AcuraBio’s assets will enable AcuraBio to advance and better serve their customers based with efficient and flexible cGMP manufacturing services that address the increasing demand for high quality therapeutics within the Australia and New Zealand region and beyond.”

According to Research and Markets, the plasmid DNA manufacturing market size is estimated to be $525.12 million in 2022 and is expected to witness a CAGR of 13.87% from 2023 to 2033. A growing public understanding of cell & gene therapy and the surging number of patients choosing gene therapy as their treatment of choice are factors contributing to the market growth.[2]

To learn more about the plasmid DNA technology, please visit the Biotech Makers Webinar .
[1]Resources for calculated benefits for pDNA downstream process at 200 L scale
-Biotech Makers webinar on Oligo and mRNA therapeutics (December 14, 2022)
-2023 Bio Trend Summit webinar (November 16, 2022)
[2]Plasmid DNA Manufacturing Global Market Report 2022: Surging Number of Patients Choosing Gene Therapy as Their Treatment to Fuel Growth

About AcuraBio
AcuraBio Pty Ltd is one of Australia’s most experienced biopharmaceutical CDMOs, offering trusted, client-focused services to both domestic and international clients for the past 20 years. AcuraBio offers significant quality, cost, and IP assurances for biopharma companies around the world. World-class researchers and proven facilities, a streamlined regulatory framework, generous tax incentives, and government funding make Australia a prime location for biotech research. AcuraBio has the following operating licenses: TGA (Australian FDA equivalent) license for the manufacture of human therapeutic APIs from biological and synthetic sources, APVMA (veterinary equivalent of the TGA) license for manufacture of sterile immunobiological products, OGTR license to produce products from genetically modified organisms, and a DAF facility license for import and use of biologic materials. Additional information about AcuraBio is available at

About Cytiva
At Cytiva, we believe the key to transforming human health is accessing life-changing therapies. That’s why our nearly 10 000 associates in more than 40 countries are keenly focused on helping researchers, biopharma companies, and drug manufacturers to advance and accelerate therapeutics for people that need them. We’re driven by their desire to achieve better flexibility, capacity, and efficiency in all facets of their work – all the way from discovery to delivery. Learn more at

Media Contact:

Iris Zhao

Source AcuraBio;Cytiva